Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Summary
This trial was designed to evaluate the safety of SHR-1819 in children and adolescents with moderate-to-severe atopic dermatitis.
Official title: A Phase Ib/II Study to Investigate the Safety、PK and PD of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
Key Details
Gender
All
Age Range
6 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
51
Start Date
2024-12-18
Completion Date
2025-11-22
Last Updated
2026-07-02
Healthy Volunteers
No
Interventions
SHR-1819 injection
SHR-1819 injection.
Locations (2)
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China